eAppendix: Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys

Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.

A clinical-note analysis of more than 1000 patients found rising off-label BPC-157 use for pain and healing, with outcomes unproven.

At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.

Frailty, but not HIV serostatus, is tied to more severe lower urinary tract symptoms in adults with and at risk for HIV, a cross-sectional study finds.

Cost and access, not side effects, drive GLP-1 discontinuation, and obesity should be covered like diabetes, says Fatima Cody Stanford, MD.

At AMCP Nexus 2026, payers said evidence, differentiation, and delivery now matter as much as FDA approval.

About one quarter of patients with overactive bladder were taking their initial oral regimen at nearly 3 years, yet most reported symptom improvement.

Alternating platelet-rich plasma and intralesional corticosteroids was well tolerated in a pediatric Asian patient with severe alopecia areata.